Golimumab (anti-TNF monoclonal antibody): where we stand today

• Главные авторы: Ana Teresa Melo (Автор), Raquel Campanilho-Marques (Автор), João Eurico Fonseca (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2021-06-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Tumor necrosis factor (TNF) is a pro-inflammatory cytokine and its overexpression has been implicated in the pathophysiology of several chronic immune-mediated inflammatory diseases. Biological therapies, like TNF inhibitors, have been revolutionizing the course of these disorders. Golimumab is a tr...